Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management.

Herrera-Caceres JO, Finelli A, Jewett MAS.

World J Urol. 2018 Jul 18. doi: 10.1007/s00345-018-2373-9. [Epub ahead of print]

PMID:
30022406
2.

The association between physician trust and prostate-specific antigen screening: Implications for shared decision-making.

Klaassen Z, Wallis CJD, Goldberg H, Chandrasekar T, Fleshner NE, Finelli A, Kulkarni GS, Detsky AS, Satkunasivam R.

Can Urol Assoc J. 2018 Jun 19. doi: 10.5489/cuaj.5351. [Epub ahead of print]

PMID:
29940136
3.

Prehabilitation for radical prostatectomy: A multicentre randomized controlled trial.

Santa Mina D, Hilton WJ, Matthew AG, Awasthi R, Bousquet-Dion G, Alibhai SMH, Au D, Fleshner NE, Finelli A, Clarke H, Aprikian A, Tanguay S, Carli F.

Surg Oncol. 2018 Jun;27(2):289-298. doi: 10.1016/j.suronc.2018.05.010. Epub 2018 May 7.

PMID:
29937184
4.

Modulating ATP Binding Cassette (ABC) Transporters in Papillary Renal Cell Carcinoma Type 2 Enhances its Response to Targeted Molecular Therapy.

Saleeb RM, Farag M, Lichner Z, Brimo F, Bartlett J, Bjarnason G, Finelli A, Rontondo F, Downes MR, Yousef GM.

Mol Oncol. 2018 Jun 13. doi: 10.1002/1878-0261.12346. [Epub ahead of print]

5.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

6.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA; Profile Study, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA.

Nat Genet. 2018 Jun 11. doi: 10.1038/s41588-018-0142-8. [Epub ahead of print]

PMID:
29892016
7.

Describing perspectives of health care professionals on active surveillance for the management of prostate cancer.

Pang K, Fitch M, Ouellet V, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, So A, Sutcliffe S, Tanguay S, Saad F, Mes-Masson AM.

BMC Health Serv Res. 2018 Jun 8;18(1):430. doi: 10.1186/s12913-018-3273-9.

8.

Statin use and time to progression in men on active surveillance for prostate cancer.

Jayalath VH, Nayan M, Finelli A, Komisarenki M, Timilshina N, Kulkarni GS, Fleshner NE, Bhindi B, Evans A, Zlotta AR, Hamilton RJ.

Prostate Cancer Prostatic Dis. 2018 Jun 6. doi: 10.1038/s41391-018-0053-x. [Epub ahead of print]

PMID:
29875433
9.

Uncoupling Diagnosis and Treatment of Incidentally Imaged Renal Masses.

Nayan M, Jewett MAS, Finelli A.

JAMA Intern Med. 2018 May 1;178(5):727-728. doi: 10.1001/jamainternmed.2018.1180. No abstract available.

PMID:
29801131
10.

Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 years of Age.

Goldberg H, Klaassen Z, Chandrasekar T, Wallis CJD, Toi A, Sayyid R, Bhindi B, Nesbitt M, Evans A, van der Kwast T, Sweet J, Perlis N, Hamilton RJ, Kulkarni GS, Finelli A, Zlotta A, Fleshner N.

J Urol. 2018 May 11. pii: S0022-5347(18)43127-8. doi: 10.1016/j.juro.2018.05.017. [Epub ahead of print]

PMID:
29758220
11.

Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes.

Komisarenko M, Martin LJ, Finelli A.

Transl Androl Urol. 2018 Apr;7(2):243-255. doi: 10.21037/tau.2018.03.02. Review.

12.

A narrative review and update on management following negative prostate biopsy.

Cheung DC, Li J, Finelli A.

Curr Opin Urol. 2018 Jul;28(4):398-402. doi: 10.1097/MOU.0000000000000509.

PMID:
29702497
13.

Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.

Ghai S, Perlis N, Lindner U, Hlasny E, Haider MA, Finelli A, Zlotta AR, Kulkarni GS, van der Kwast TH, McCluskey SA, Kucharczyk W, Trachtenberg J.

Eur Radiol. 2018 Apr 25. doi: 10.1007/s00330-018-5409-z. [Epub ahead of print]

PMID:
29696431
14.

First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

Wallis CJD, Klaassen Z, Bhindi B, Ye XY, Chandrasekar T, Farrell AM, Goldberg H, Boorjian SA, Leibovich B, Kulkarni GS, Shah PS, Bjarnason GA, Heng DYC, Satkunasivam R, Finelli A.

Eur Urol. 2018 Apr 13. pii: S0302-2838(18)30254-9. doi: 10.1016/j.eururo.2018.03.036. [Epub ahead of print] Review.

PMID:
29656851
15.

Is routine use of renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses?

Richard PO, Lavallée LT, Pouliot F, Komisarenko M, Martin L, Latouff JB, Finelli A.

J Urol. 2018 Apr 10. pii: S0022-5347(18)42925-4. doi: 10.1016/j.juro.2018.04.015. [Epub ahead of print]

PMID:
29653161
16.

Identifying the use and barriers to the adoption of renal tumour biopsy in the management of small renal masses.

Richard PO, Martin L, Lavallée LT, Violette PD, Komisarenko M, Evans AJ, Jain K, Jewett MAS, Finelli A.

Can Urol Assoc J. 2018 Apr 6. doi: 10.5489/cuaj.5065. [Epub ahead of print]

PMID:
29629862
17.

A UHPLC-MS/MS-based method for the simultaneous monitoring of eight antiblastic drugs in plasma and urine of exposed healthcare workers.

Izzo V, Charlier B, Bloise E, Pingeon M, Romano M, Finelli A, Vietri A, Conti V, Manzo V, Alfieri M, Filippelli A, Dal Piaz F.

J Pharm Biomed Anal. 2018 May 30;154:245-251. doi: 10.1016/j.jpba.2018.03.024. Epub 2018 Mar 13.

PMID:
29558725
18.

The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer.

Perlis N, Krahn MD, Boehme KE, Alibhai SMH, Jamal M, Finelli A, Sridhar SS, Chung P, Gandhi R, Jones J, Tomlinson G, Bremner KE, Kulkarni G.

J Urol. 2018 Aug;200(2):283-291. doi: 10.1016/j.juro.2018.03.006. Epub 2018 Mar 9.

PMID:
29530786
19.

Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.

Benidir T, Hersey K, Finelli A, Hamilton R, Joshua AM, Kulkarni G, Zlotta A, Fleshner N.

Urol Oncol. 2018 May;36(5):240.e13-240.e20. doi: 10.1016/j.urolonc.2018.01.011. Epub 2018 Feb 15.

PMID:
29454590
20.

A miRNA-based classification of renal cell carcinoma subtypes by PCR and in situ hybridization.

Di Meo A, Saleeb R, Wala SJ, Khella HW, Ding Q, Zhai H, Krishan K, Krizova A, Gabril M, Evans A, Brimo F, Pasic MD, Finelli A, Diamandis EP, Yousef GM.

Oncotarget. 2017 Dec 8;9(2):2092-2104. doi: 10.18632/oncotarget.23162. eCollection 2018 Jan 5.

21.

Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.

Prendeville S, Gertner M, Maganti M, Pintilie M, Perlis N, Toi A, Evans AJ, Finelli A, van der Kwast TH, Ghai S.

J Urol. 2018 Jul;200(1):104-113. doi: 10.1016/j.juro.2018.01.081. Epub 2018 Feb 2.

PMID:
29408568
22.

Case - Foamy, high-grade prostatic intraepithelial neoplasia: A false positive for prostate cancer on multiparametric magnetic resonance imaging?

Chandrasekar T, Goldberg H, Klaassen Z, Perlis N, Finelli A, Evans A, Ghai S.

Can Urol Assoc J. 2018 May;12(5):E256-E259. doi: 10.5489/cuaj.4860. Epub 2018 Feb 6. No abstract available.

23.

Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives.

Sayyid RK, Sayyid AK, Klaassen Z, Hersey K, Goldberg H, Perlis N, Ahmad A, Leao R, Chandrasekar T, Fadaak K, Madi R, Terris MK, Finelli A, Hamilton RJ, Kulkarni GS, Zlotta AR, Fleshner NE.

Can Urol Assoc J. 2018 May;12(5):E210-E218. doi: 10.5489/cuaj.4922. Epub 2018 Feb 6.

24.

An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.

Liede A, Wade S, Lethen J, Hernandez RK, Warner D, Abernethy AP, Finelli A.

Clin Ther. 2018 Apr;40(4):536-549.e3. doi: 10.1016/j.clinthera.2017.12.015. Epub 2018 Feb 1.

PMID:
29395290
25.

Implementing robot-assisted radical prostatectomy - one for all and all for one.

Finelli A.

Can Urol Assoc J. 2018 Feb;12(2):44. doi: 10.5489/cuaj.5076. Epub 2017 Dec 1. No abstract available.

26.

Recommandations de l'Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.

Rendon RA, Mason RJ, Marzouk K, Finelli A, Saad F, So A, Violette P, Breau RH.

Can Urol Assoc J. 2017 Oct;11(10):298-309. doi: 10.5489/cuaj.4888. No abstract available.

27.

Laparoscopic Approach for Shull Repair of Pelvic Floor Defects.

Restaino S, Ronsini C, Finelli A, Santarelli A, Scambia G, Fanfani F.

J Minim Invasive Gynecol. 2017 Dec 28. pii: S1553-4650(17)31357-2. doi: 10.1016/j.jmig.2017.12.016. [Epub ahead of print]

PMID:
29289624
28.

Challenges Interpreting Chemoprevention Studies Using Observational Data.

Nayan M, Juurlink DN, Finelli A, Kulkarni G, Hamilton RJ.

J Clin Oncol. 2018 Feb 20;36(6):628-629. doi: 10.1200/JCO.2017.76.1064. Epub 2017 Dec 20. No abstract available.

PMID:
29261441
29.

Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer.

Berlin A, Ahmad AE, Chua MLK, Moraes FY, Jiang H, Komisarenko M, Trimilshina N, Raziee H, Hosni A, Murgic J, Chung P, Bristow RG, Finelli A.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):702-709. doi: 10.1016/j.ijrobp.2017.10.041. Epub 2017 Nov 1.

PMID:
29249526
30.

Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study.

Dragomir A, Aprikian A, Kapoor A, Finelli A, Pouliot F, Rendon R, Black PC, Moore R, Breau RH, Kawakami J, Drachenberg D, Lattouf JB, Tanguay S.

CMAJ Open. 2017 Dec 11;5(4):E834-E841. doi: 10.9778/cmajo.20170005.

31.

Medication use and kidney cancer survival: A population-based study.

Nayan M, Juurlink DN, Austin PC, Macdonald EM, Finelli A, Kulkarni GS, Hamilton RJ; Canadian Drug Safety and Effectiveness Research Network (CDSERN).

Int J Cancer. 2018 May 1;142(9):1776-1785. doi: 10.1002/ijc.31204. Epub 2018 Jan 3.

PMID:
29226327
32.

Role of blue dye for sentinel lymph node detection in early endometrial cancer.

Restaino S, Ronsini C, Finelli A, Perrone E, Scambia G, Fanfani F.

Gynecol Surg. 2017;14(1):23. doi: 10.1186/s10397-017-1026-0. Epub 2017 Nov 29.

33.

Environmental and economic benefits of the recovery of materials in a municipal solid waste management system.

De Feo G, Ferrara C, Finelli A, Grosso A.

Environ Technol. 2017 Dec 7:1-9. doi: 10.1080/09593330.2017.1411395. [Epub ahead of print]

PMID:
29187068
34.

Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect.

Perlis N, Al-Kasab T, Ahmad A, Goldberg E, Fadak K, Sayid R, Finelli A, Kulkarni G, Hamilton R, Zlotta A, Ghai S, Fleshner N.

J Urol. 2018 May;199(5):1182-1187. doi: 10.1016/j.juro.2017.11.074. Epub 2017 Nov 23. Erratum in: J Urol. 2018 Jul 12;:.

PMID:
29175542
35.

Active Surveillance in Small Renal Masses in the Elderly: A Literature Review.

Cheung DC, Finelli A.

Eur Urol Focus. 2017 Oct;3(4-5):340-351. doi: 10.1016/j.euf.2017.11.005. Epub 2017 Nov 23. Review.

PMID:
29175368
36.

Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines.

Klaassen Z, Arora K, Goldberg H, Chandrasekar T, Wallis CJD, Sayyid RK, Fleshner NE, Finelli A, Kutikov A, Violette PD, Kulkarni GS.

J Urol. 2018 Apr;199(4):906-914. doi: 10.1016/j.juro.2017.08.130. Epub 2017 Nov 4. Review.

PMID:
29113840
37.

Canadian Men's perspectives about active surveillance in prostate cancer: need for guidance and resources.

Fitch M, Pang K, Ouellet V, Loiselle C, Alibhai S, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, Sutcliffe S, So A, Tanguay S, Saad F, Mes-Masson AM.

BMC Urol. 2017 Oct 27;17(1):98. doi: 10.1186/s12894-017-0290-7.

38.

Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance.

Chandrasekar T, Ahmad AE, Fadaak K, Jhaveri K, Bhatt JR, Jewett MAS, Finelli A.

J Urol. 2017 Sep 20. pii: S0022-5347(17)77564-7. doi: 10.1016/j.juro.2017.09.078. [Epub ahead of print]

PMID:
28941915
39.

Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective.

Lawson KA, Saarela O, Liu Z, Lavallée LT, Breau RH, Wood L, Jewett MAS, Kapoor A, Tanguay S, Moore RB, Rendon R, Pouliot F, Black PC, Kawakami J, Drachenberg D, Finelli A.

Can Urol Assoc J. 2017 Aug;11(8):232-237. doi: 10.5489/cuaj.4397.

40.

Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Tomlinson GA, Winquist E.

Ann Intern Med. 2017 Sep 5;167(5):341-350. doi: 10.7326/M16-2577. Epub 2017 Aug 8. Review.

PMID:
28785760
41.

Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.

Bhindi B, Jiang H, Poyet C, Hermanns T, Hamilton RJ, Li K, Toi A, Finelli A, Zlotta AR, van der Kwast TH, Evans A, Fleshner NE, Kulkarni GS.

Urol Oncol. 2017 Oct;35(10):604.e17-604.e24. doi: 10.1016/j.urolonc.2017.06.044. Epub 2017 Aug 7.

PMID:
28781111
42.

Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC).

Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, Vanhuyse M, Tanguay S, Finelli A, Jewett MAS, Basappa N, Lattouf JB, Gotto GT, Al-Asaaed S, Bjarnason GA, Moore R, North S, Canil C, Pouliot F, Soulières D, Castonguay V, Kassouf W, Cagiannos I, Morash C, Breau RH.

J Cancer Educ. 2017 Aug 4. doi: 10.1007/s13187-017-1259-7. [Epub ahead of print]

PMID:
28779441
43.

Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice.

Sayyid RK, Sayyid AK, Klaassen Z, Fadaak K, Goldberg H, Chandrasekar T, Ahmad A, Leao R, Perlis N, Chadwick K, Hamilton RJ, Kulkarni GS, Finelli A, Zlotta AR, Fleshner NE.

J Urol. 2018 Jan;199(1):251-256. doi: 10.1016/j.juro.2017.07.078. Epub 2017 Jul 25.

PMID:
28751266
44.

Medication use and kidney cancer risk: A population-based study.

Nayan M, Juurlink DN, Austin PC, Macdonald EM, Finelli A, Kulkarni GS, Hamilton RJ; Canadian Drug Safety and Effectiveness Research Network (CDSERN).

Eur J Cancer. 2017 Sep;83:203-210. doi: 10.1016/j.ejca.2017.07.001. Epub 2017 Jul 24.

PMID:
28750272
45.

Exosomal MicroRNAs Are Diagnostic Biomarkers and Can Mediate Cell-Cell Communication in Renal Cell Carcinoma.

Butz H, Nofech-Mozes R, Ding Q, Khella HWZ, Szabó PM, Jewett M, Finelli A, Lee J, Ordon M, Stewart R, Krylov S, Yousef GM.

Eur Urol Focus. 2016 Jun;2(2):210-218. doi: 10.1016/j.euf.2015.11.006. Epub 2015 Dec 12.

PMID:
28723537
46.

The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis.

Bhindi B, Wallis CJD, Nayan M, Farrell AM, Trost LW, Hamilton RJ, Kulkarni GS, Finelli A, Fleshner NE, Boorjian SA, Karnes RJ.

JAMA Intern Med. 2017 Sep 1;177(9):1273-1286. doi: 10.1001/jamainternmed.2017.2791.

PMID:
28715534
47.

Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative.

Bansal RK, Tanguay S, Finelli A, Rendon R, Moore RB, Breau RH, Lacombe L, Black PC, Kawakami J, Drachenberg D, Pautler S, Saarela O, Liu Z, Jewett MAS, Kapoor A.

Can Urol Assoc J. 2017 Jun;11(6):182-187. doi: 10.5489/cuaj.4264.

48.

The value of complementing administrative data with abstracted information on smoking and obesity: A study in kidney cancer.

Nayan M, Hamilton RJ, Finelli A, Austin PC, Kulkarni GS, Juurlink DN.

Can Urol Assoc J. 2017 Jun;11(6):167-171. doi: 10.5489/cuaj.4569.

49.

Psychological distress and lifestyle disruption in low-risk prostate cancer patients: Comparison between active surveillance and radical prostatectomy.

Matthew AG, Raz O, Currie KL, Louis AS, Jiang H, Davidson T, Fleshner NE, Finelli A, Trachtenberg J.

J Psychosoc Oncol. 2018 Mar-Apr;36(2):159-174. doi: 10.1080/07347332.2017.1342733. Epub 2017 Aug 8.

PMID:
28613997
50.

Critical appraisal of the application of propensity score methods in the urology literature.

Nayan M, Hamilton RJ, Juurlink DN, Finelli A, Kulkarni GS, Austin PC.

BJU Int. 2017 Dec;120(6):873-880. doi: 10.1111/bju.13930. Epub 2017 Jul 7.

PMID:
28608364

Supplemental Content

Loading ...
Support Center